Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 12/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | USP2 | O75604 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23564349 | 0.82 | KDM1A (0.39) | CYP2D6SMN1; SMN2KDM1ACYP2C19CYP2C9 | |
| SCHEMBL23126878 | 0.76 | — | — | |
| SCHEMBL18084598 | 0.75 | — | — | |
| SCHEMBL23270102 | 0.75 | KDM1A (0.41) | CYP2D6SMN1; SMN2KDM1ACYP2C19CYP2C9 | |
| SCHEMBL23841640 | 0.75 | — | — | |
| SCHEMBL22893236 | 0.73 | SLC6A2 (0.32) | — | |
| SCHEMBL27059851 | 0.73 | CYP2D6 (0.48) | CYP2D6SMN1; SMN2CYP2C19CYP2C9TSHR | |
| SCHEMBL13929775 | 0.72 | CYP2D6 (0.43) | CYP2D6SMN1; SMN2CYP2C19CYP2C9TSHR | |
| SCHEMBL25626550 | 0.71 | CYP2D6 (0.53) | CYP2D6SMN1; SMN2KDM1ACYP2C19CYP2C9 | |
| SCHEMBL22021012 | 0.71 | KDM1A (0.32) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019236-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2023-01-19 | — | — | US | disclosed |
| US-20210009542-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | ABBVIE INC. | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019236-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN1, PTPN2, PTPN18 | CYP2D6 3885/4885SMN1; SMN2 3496/4885KDM1A 1844/4885 |
| US-20210009542-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN1, PTPN2, PTPN18 | CYP2D6 3885/4885SMN1; SMN2 3496/4885KDM1A 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.